Introduction
Diagnostic imaging technologies have been used to try to monitor transgene expression for gene therapy using MRI, optical imaging, and radionuclide imaging techniques including PET and SPECT. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Reporter genes with optical signatures (eg, fluorescence and bioluminescence) are low-cost alternatives for real-time analysis of gene expression in small animal models. Fluorescence imaging uses a fluorescent protein such as green fluorescent protein (GFP) that is excited with external illumination, and the emission is subsequently detected. 11 GFPencoding cDNA can easily be included in the myriad of therapeutic vectors and serve as a monitoring tool for gene therapy. Nevertheless, excitation and emission wavelengths in the range of 500 nm (eg, GFP) have limited penetration in mammalian tissues (1-5 mm) . Since mammalian tissues absorb light that is used to excite these fluors, the tissues also fluoresce when excited at these wavelengths. The combination of absorption of specific signal and autofluorescence of tissues can result in poor signal-to-noise. 3 Recently, red-shifted mutants of GFP (RFP) have been known to have an advantage over GFP that red light penetrates tissues more efficiently than green. 12 Bioluminescent photoproteins such as luciferase have been used as reporter proteins in living animals. 2, 13, 14 Firefly luciferase (FL) catalyzes D-luciferin to produce oxyluciferin in the presence of oxygen, cofactors, Mg , and ATP to produce light with peak at 562 nm. Recently, validated renilla luciferase (RL) catalyzes the oxidation of coelenterazine in the presence of oxygen, to generate a flash of blue luminescence with a peak wavelength at 482 nm. The advantage of bioluminescence is the minimal background noise, since luciferase is not a natural constituent of mammalian organisms. Bioluminescence-based approaches currently lack detailed tomographic information, and are limited to relatively small animals. 10, 15, 16 A newer approach to fluorescence imaging of deeper structures uses fluorescence-mediated tomography. 17 The subject is exposed in an imaging chamber to continuous wave or pulsed light from different sources, and detectors arranged in a spatially defined order capture the emitted light. Mathematical processing of this information results in a reconstructed tomographic image. Fluorescencemediated tomography is still in its infancy, requiring extensive mathematical validation prior to routine implementation. The advantage of MR for the imaging of gene expression is the excellent three-dimensional spatial resolution (tens of mm range) at imaging. Owing to the indirect nature of enhancement produced by MR contrast agents, much higher concentrations of injected material, on the order of 10-100 mM concentrations and higher, are generally necessary to produce sufficient image contrast. 2, 3, 6, 7, 10 The low sensitivity often entails long imaging times, and consequently slow data acquisition. 7 While magnetic resonance spectroscopy (MRS) does not usually produce three-dimensional images, the technique does provide accurate measurement of gene expression in short time frames, and may eventually be harnessed to produce true spatial images, but at a much poorer spatial resolution than MRI. Radionuclide imaging with PET and SPECT has been used to characterize enzyme activity, receptor/transporter status, and biodistribution of various radiolabeled substrates (tracers). 8 For these reasons, it has made the most significant progress for imaging gene therapy by monitoring gene delivery and identifying therapeutic and/or reporter gene expression in living subjects. While sensitivity in PET imaging is high (as little as 10
À11
-10 À12 M of tracer can be detected) and the speed of imaging is relatively rapid (min), these techniques lack micrometer spatial resolution (1-2 mm with micro-PET). 3, 7, 9 An alternative approach to PET is SPECT imaging. While the sensitivity of the single-photon system is intrinsically about one -to two orders of magnitude less than PET systems, the required radiopharmaceuticals and imaging systems are more readily available. Further details of the instrumentation available and relative advantages between the various types of imaging instrumentation may be found elsewhere. 1, 2, 18 In the following sections, we will review several imaging technologies for monitoring gene delivery or transgene expression. Much of the current focus of molecular imaging in gene therapy is directed towards oncological applications; however, preliminary studies for cardiovascular and neurological applications have also been reported. All the applications are briefly described in the text and are also summarized in Tables 1 and 2 .
Oncology
Radionuclide imaging Imaging the vector utilized for gene delivery. To assess the efficiency of vector delivery, radionuclide imaging can be used to look at the distribution of the radiolabeled vector itself. The ideal gene therapy paradigm for brain tumors may consist of a combination of intratumoral injection and intra-arterial administration of vectors bearing therapeutic transgenes. In previous studies, herpes simplex virus (HSV) was radiolabeled with lipophilic [
111 In]-oxine complex to be administered to intracerebral glioma-bearing rats. Intracarotid injection of radiolabeled HSV revealed the low efficiency of viral uptake in the tumor (0.10% of the injected dose per gram of tissue) at 1 h. When animals received virus injections stereotactically into the tumor, 71.3735.0% of the total dose was found in the tumor at 24 h. 19 Imaging of nonviral vector delivery has been studied for direct visualization of the distribution of doublestranded DNA (pCMV-GFP). The generic structure of the probe comprises three elements: (1) a peptide-based chelate that binds the [ 99m Tc]; (2) a positively charged linker for binding to DNA phosphodiester backbone; (3) an intercalating psoralen group. 22 The formation of a stable complex between the probe and the DNA is achieved by ultraviolet crosslinking of psoralen and DNA. The feasibility of imaging the delivery of plasmid DNA was shown in normal and tumor-bearing animals using gamma camera imaging. The nonviral genetic vector pegylated liposome was also radiolabeled to monitor the gene delivery. A preliminary study demon- 23 and therefore strongly supported the use of pegylated liposome as a targeting vehicle of therapeutic gene for solid tumors. The imaging of gene delivery in vivo could serve as a general predictor of the ability of the viral or nonviral vectors to reach the tissue(s) of interest. However, mere visualization of exogenous DNA accumulation at a certain site in the body might not correlate with the expression levels of desired gene product.
Imaging cell trafficking. In vivo imaging of cell trafficking has been investigated in many immunological and oncological studies to track the selective recruitment and time of arrival and departure of specific cells. These studies may be useful for investigators using various cell types transfected with gene(s) of interest. Tracking the migration of cells in living small animals has been performed with radionuclide, [24] [25] [26] [27] [28] [29] MR, 30, 31 and both fluorescence 32 and bioluminescence 33 optical imaging. Radionuclide imaging has been used to monitor the trafficking of therapeutic cells in living subjects. For example, gene-modified ovarian cancer cells expressing HSV1-tk (PA1-STK) were radiolabeled with [ 99m Tc] and infused into the pleural space of patients with malignant pleural mesothelioma for suicide gene therapy. Radiolabeled PA1-STK cells adhere preferentially to intrapleural mesothelioma deposits, and are retained for at least 24 h in the chest cavity. 24 Rat glioma (C6) cells and lymphocytes were radiolabeled using [ MicroPET images indicated trafficking of tail-veininjected C6 cells to the lungs and liver, and transient splenic accumulation of lymphocytes at 3.33 h postinfusion. Reporter gene imaging is also being used to follow the specific localization and expansion of adoptively transferred immune T lymphocytes to the antigenpositive tumor and other sites within the animal. 28, 29 This approach can be used to assess the effects of immunomodulatory agents intended to potentiate the immune response to cancer, and can also be useful for the study of other cell-mediated immune responses, including autoimmunity.
Imaging therapeutic gene expression. Radionuclide imaging technologies, especially PET and SPECT, can play a significant role in imaging gene expression using diverse reporter genes and reporter probes. A reporter gene can be introduced into the target tissue(s) by various methods including viral and nonviral delivery vectors. If the promoter leads to transcription of the reporter gene, then translation of the imaging reporter gene mRNA leads to a protein product which can interact with the imaging reporter probe (administered in trace amounts for PET/SPECT and sometimes referred to as a tracer). This interaction may be based on intracellular enzymatic conversion of the reporter probe with retention of the metabolite(s), or a receptor-ligandbased interaction. Examples of intracellular reporters include herpes simplex virus type 1 thymidine kinase (HSV1-tk) and its mutant gene (HSV1-sr39tk). 34 Note that HSV1-tk or HSV1-sr39tk refers to the genes and HSV1- Noninvasive imaging of gene therapy JJ Min and SS Gambhir TK or HSV1-sr39TK refers to the respective enzymes.
Substrates that have been studied to date as PET reporter probes for HSV1-TK can be classified into two main categories -pyrimidine nucleoside derivatives (eg, 5-iodo-2 0 -fluoro-2 0 -deoxy-1-b-D-arabinofuranosyluracil (FIAU)) and acycloguanosine derivatives (eg, 9-(4-fluoro-3-hydroxymethylbutyl)guanine (FHBG)), and have been studied in terms of sensitivity and specificity. 35, 36 Examples of reporters on or in the cell surface in the form of receptors include the dopamine 2 receptor (D 2 R), 37 receptors for human type 2 somatostatin receptor (hSSTr2), 38 and the sodium iodide symporter (NIS). 39, 40 Among these reporter genes, the HSV1-tk gene may alter the cellular behavior towards apoptosis by changes in the dNTP pool, 41 and receptors may result in second messenger activation such as triggering of signal transduction pathways. For the D 2 R system, a mutant gene has been studied, which shows uncoupling of signal transduction but preservation of the affinity of receptor for tracer ligand. 42 The reporter gene can itself be the therapeutic gene or can be coupled to the therapeutic gene. 9 In the former approach, the reporter gene and therapeutic gene are one and the same. For example, anticancer gene therapy using HSV1-tk and ganciclovir (GCV) can be coupled with imaging of the accumulation of radiolabeled probes ( 45-48 NIS has many advantages as an imaging reporter gene that includes wide availability of its substrates, well-understood metabolism, and clearance of these substrates in the body, and no likely interaction with the underlying cellular biochemistry. Since the iodine is not trapped, issue of efflux has to be optimized, but initial studies show significant promise. Further studies are needed with regard to NIS as an imaging reporter gene.
A second approach involves indirect imaging of therapeutic transgene expression using expression of a reporter gene, which is coupled to a therapeutic transgene of choice. This strategy requires proportional and constant co-expression of both the reporter gene and the therapeutic gene over a wide range of transgene expression levels. An advantage of this approach is that it provides for a much wider application of therapeutic transgene imaging, because various imaging reporter genes can be coupled to various therapeutic transgenes, while utilizing the same imaging probe each time. Linking the expression of a therapeutic gene to a reporter gene has been validated using PET through a variety of different molecular constructs. Examples include fusion approaches, [49] [50] [51] bicistronic approaches using internal ribosomal entry site (IRES), [52] [53] [54] dual-promoter approaches, 55 ,56 a bidirectional transcriptional approach, 57 and a two-vector administration approach. 58 An advantage of the fusion gene approach is that the expression of the linked genes is absolutely coupled (unless the spacer between the two proteins is cleaved). However, the 53 This can lead to a lower imaging sensitivity, and methods to improve this approach are currently under investigation. 54 Two different genes expressed from distinct promoters within a single vector (dual-promoter approach) may avoid some of the attenuation and tissue-variation problems of an IRES-based approach. 55 The potential problem of this approach is that the expression of the two genes may become uncoupled if the two identical promoters have different transcriptional activity based on where the vector integrates into the host genome or if a mutation occurs in one or both promoters that changes transcriptional activity. A bidirectional transcriptional approach utilizes a vector in which the therapeutic and the reporter genes are driven by each minimal CMV promoter induced by tetracycline-responsive element (TRE), transcribing separated mRNA from each gene which would then be translated into separate protein products. 57 This system also avoids the attenuation and tissue-variation problems of the IRES-based approach, and may prove to be one of the most robust approaches developed to date. It is limited by the fact that a fusion protein also needs to be co-expressed, but future vectors should be able to encode for both the fusion protein and the bidirectional transcriptional system on a single vector. Another way to image both the therapeutic and reporter genes can be through administration of two separate vectors, by cloning of the therapeutic and reporter genes in two different vectors, but driven by same promoter. This system may eliminate the need for making a new construct for each therapeutic gene, and has been validated through the expression of two PET reporter genes and showed good correlation. 58 However, it is important to realize that the trans effects between two promoters can potentially affect reporter gene expression, and that not all cells may be equally infected with the PET reporter gene vector and therapeutic gene vector.
Tumor-restricted gene expression through tissue-specific transcriptional targeting is an attractive approach for gene therapy. It has been demonstrated that gene expression of highly efficient gene therapy vectors can be targeted to tumors using cell-type or tissue-type specific promoter elements. Approaches have also been developed to image the transcriptional regulation of the PET reporter gene in living animals. 27, 57, 59 For example, transcriptional regulation at the level of induction has been reported in living mice using two PET imaging reporter genes (HSV1-tk and D 2 R) under the control of a tetracycline-inducible promoter. 57 Using PET, correlative expression of both reporters after doxycycline treatment was measured in animals harboring stably transfected tumor. Low levels of imaging reporter gene expression owing to relatively weak tissue-specific promoters were circumvented with VP16 transactivating domains fused to yeast GAL4 DNA-binding domains. This two-step transcriptional amplification (TSTA) system was valuable in demonstrating PSE-or CEA-driven reporter gene expression in vivo using HSV1-sr39tk or HSV1-tk under the control of GAL4-responsive elements. [60] [61] [62] [63] [64] [65] Further studies are necessary to link this system to amplify both therapeutic and reporter gene expression. These approaches hold significant promise for the development of tissue-specific vectors with high levels of gene expression.
The lytic properties of herpes, adeno or Newcastle viruses are also being tailored for the destruction of various tumors. Although these oncolytic viruses are promising agents for treatment of malignancy due to their direct, selective toxicity for tumor cells, it is not easy to document viral replication in living subjects, as serial tissue sampling was required to assess viral titers over time. [ 124 I]FIAU PET scanning was capable of distinguishing a half-log difference between viral doses, and was able to document viral proliferation in xenograft tumor infected by oncolytic HSV infection. 66, 67 This PET data might provide a new direction for evaluating viral infection and proliferation in future clinical trials involving oncolytic viral therapy.
MRI and MRS
In spite of its high spatial resolution (10-100 mm), MR imaging has only a micromolar sensitivity to paramagnetic contrast agents, so robust signal-amplification strategies are necessary. Relatively large amounts of reporter probe (metals) have to accumulate in cells in order to lead to signal changes that can be imaged in the MR scanner. Targeted MR contrast agents in conjunction with biochemical amplification strategies have been preliminarily studied. Studies highlight the use of the transferrin receptor (Tf-R) as a potential transporter for accumulation of contrast agents, which consist of human holotransferrin covalently conjugated to low-molecularweight dextrans coating monocrystalline iron oxide nanoparticles (Tf-MION) 68, 69 or crosslinked iron oxide (Tf-CLIO). 70 The transferrin is recognized by the receptor and the entire particle is endocytosed by the cell, bringing in iron, a paramagnetic ion that acts as a contrast agent by affecting the T 2 rate. It has been demonstrated that overexpression of the Tf-R in rat gliosarcoma cells in conjunction with the Tf-MION successfully increases the iron content in the cells, such that measurable MRI contrast can be achieved in living mice implanted with tumors. Further studies are under investigation to verify whether the Tf-R can be engineered to coexpress with a therapeutic gene, 70 and are necessary to assess the effect of overexpressing Tf-R and increased level of iron on normal cellular function.
Contrast agents that change the magnetic properties at enzymatic hydrolysis have been used recently to image transgene expression. Contrast agents, (1-(2-(b-galactopyranosyloxy)propyl)-4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododecane)gadolinium(III) (EgadMe), are based on the framework of a clinical constrast agent, Gd(HP-DO3A), that has been modified with a carbohydrate 'cap' that blocks the access of water to the gadolinium. When access of water to gadolinium is blocked, signal enhancement by the contrast agent is turned 'off'. The cap is attached to the contrast agent through a b-galactosidasecleavable linker. Enzyme cleavage releases the cap and opens water access to the gadolinium ion, turning the contrast agent 'on'. 71 Experiments in Xenopus embryo system revealed regions of higher intensity in the MR 71 In this report, the contrast agent was introduced to animal systems by microinjection. Such application will require further refinement of the contrast agents in order to be delivered to cells without direct injection.
The ability of MRS to distinguish signals from chemically distinct compounds also offers the potential to measure gene expression. Conversion of the nontoxic prodrug 5-fluorocytosine (5-FC) to the chemotherapeutic agent 5-fluorouracil (5-FU) by yeast cytosine deaminase (yCD) could be observed and quantitated in colorectal tumor xenograft in living subjects, using 19 F MRS. 72 This study demonstrates the feasibility of using MRS to noninvasively monitor therapeutic transgene expression in tumors.
Optical imaging
A variety of different optical imaging approaches have been used to image gene expression in living subjects in optically transparent organisms. Using adenovirus encoding GFP as a reporter gene and illumination in a light box by blue light fiber optics, noninvasive, whole-body, real-time fluorescence optical imaging of transgene expression was demonstrated in the major organs of nude mice including the brain and liver. 11 GFP also has been used to image the transduction of lentivirus in nondividing hepatocytes in living nude mice. 73 Bioluminescence imaging exploits the emission of visible photons at specific wavelengths, on the basis of energy-dependent reactions catalyzed by various luciferases.
14, 16 The emitted photons can be detected and counted using low-light CCDs or photon-counting cameras. The kinetics of gene expression after vector administration has been examined by injecting lentiviral vector encoding FL. 74 To improve the activity and specificity of prostatetargeted gene expression, enhanced promoters were developed by multimerizing key regulatory elements in the prostate-specific antigen (PSA) enhancer and promoter. The resulting PSE-BC construct was incorporated into an adenovirus vector with FL (AdPSE-BC-luc), and applied in the prostate cancer model to identify metastases. Cooled CCD camera imaging localized and illuminated metastases in the lung and spine, and demonstrated the potential use of noninvasive imaging modality in therapeutic and diagnostic strategies for prostate cancer (Figure 1) . 75 This tissue-specific approach was also applied to the TSTA system, and revealed 20-fold higher levels of expression than the cytomegalovirus enhancer. 60, 63, 65 These approaches were partly validated in a clinically relevant imaging modality such as micro-PET, as mentioned earlier; 61, 62 however, these approaches are still in need of further studies.
Different kinds of nonviral vectors have been evaluated in the small animal model using optical imaging techniques. The cationic lipid 1,2-dioleoyl-3-trimethyl ammonium-propane (DOTAP):cholesterol DNA liposome complexes 76 and transferrin targeted DNA/polyethylenimine (PEI) complexes 77 were evaluated with FL reporter gene imaging.
Cardiovascular disease
Gene therapy holds much promise as a potential treatment for various cardiovascular diseases. These treatments include the prevention of restenosis after angioplasty, promotion of angiogenesis, and treatment of end-stage heart failure. 78 Initial studies using autoradiography detected the uptake of [
125 I]FIAU in rat myocardium transduced with adenoviral-mediated HSV1-tk reporter gene. The authors hypothesized that in vivo cardiac gene imaging is feasible and may eventually be used for the noninvasive monitoring of gene therapy. 79 The first demonstration 80 The optical study was validated in a clinically relevant microPET (Figure 2 ). Rat myocardium was transduced with adenovirus carrying HSV1-sr39tk. The presence of [ 18 F]FHBG uptake in microPET images was confirmed by gamma counting and the presence of HSV1-sr39TK protein by thymidine kinase enzyme assay, while utilizing myocardial tissue samples. 81 More detailed quantitative microPET studies have also been performed using the same model. 82 Further studies are under investigation to construct bicistronic vectors containing both therapeutic (eg, VEGF) and PET reporter genes. 83 Recently, we developed novel imaging approaches that allow noninvasive assessment of myocardial response to cell therapy using embryonic cardiomyoblasts expressing HSV1-sr39tk and/or FL. 84 The location, magnitude, and survival duration of the transplanted cells were monitored noninvasively using PET and bioluminescence optical imaging.
Neurological applications
Both the HSV1-tk/HSV1-sr39tk and the D 2 R PET reporter genes are not optimal for most central nervous system application. All the reporter probes for HSV1-tk/ HSV1-sr39tk developed to date show very poor penetration across the blood-brain barrier (BBB). Therefore, imaging with any of these reporter probes may be useful only if some BBB disruption is present (eg, brain tumors 88 Creatine kinase (CK) and arginine kinase (AK) expression was monitored by using 31 P MRS in the liver and skeletal muscle. 89, 90 Walter et al 89 have introduced Drosophila melanogaster AK as a reporter gene for MRS detection of gene therapy of muscle diseases. This enzyme phosphorylates arginine, leading to the production of arginine phosphorylate, a unique metabolite that is not otherwise found in mammalian tissues and is readily detected by 31 P MRS. CK is expressed primarily in the muscle (MM isoform) and brain (BB isoform), but is absent in the liver, kidney, and pancreas. In a recent study, syngeneic enzyme CK was used as a reporter gene for in vivo monitoring of gene expression after virally mediated gene transfer to the liver, the key target for gene therapy applications. 90 
Future prospects
Molecular imaging strategies associated with gene therapy will likely expand significantly over the next few years as gene therapy continues to evolve. The explosion in genetic engineering is expected to generate more robust gene-transfer vectors, both viral and nonviral. Bicistronic/bidirectional vectors that can be easily modified, and tissue-specific amplification techniques, will likely expand. Continued refinements in the chemistry of molecular probe development should give rise to a new generation of probes with greater sensitivity and specificity. Advances in detector technology and image reconstruction techniques for PET should help to produce a newer generation of imaging instruments with better spatial resolution, sensitivity, and significantly improved throughput time. The optical technologies including fluorescence tomography may allow optical strategies to be the method of choice for small animal gene therapy research. Multimodality reporter gene approaches, so that gene therapy investigators may readily move between the various technologies, should help to also test various preclinical models. It will be very important for preclinical imaging strategies to be extended into patient studies where gene therapy is directly or indirectly monitored throughout the use of state-of-art imaging. Ultimately, all of the imaging technologies of gene delivery and/or expression will be used as an early measure of successful gene therapy in patients.
